PubMed
Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I
Ballard FJ, Wallace JC, Francis GL, et al. Int J Biochem Cell Biol. 1996
GH SecretagoguesResearch Only — Preclinical EvidenceA
IGF-1 DES
des(1-3)IGF-1 / Truncated IGF-1
IGF-1 DES (des(1-3)IGF-1) is a truncated 67-amino-acid analog of insulin-like growth factor-1 missing the N-terminal Gly-Pro-Glu tripeptide. Reduced IGF-binding protein affinity leaves more free peptide for IGF-1 receptor activation, yielding roughly 2–10× potency vs native IGF-1 in preclinical assays — but a very short ~20–30 minute half-life. Evidence is almost entirely animal/cell literature; not FDA-approved.
Last reviewed . First published . By the PeptIQ team.
Observational report only — modeled community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 10
- Research grade
- A
- Experience
- 70
- Activity
- 68
Overall check-ins
Trackers & reports
Overview
About IGF-1 DES
IGF-1 DES (des(1-3)IGF-1) is a truncated 67-amino-acid analog of insulin-like growth factor-1 missing the N-terminal Gly-Pro-Glu tripeptide. Reduced IGF-binding protein affinity leaves more free peptide for IGF-1 receptor activation, yielding roughly 2–10× potency vs native IGF-1 in preclinical assays — but a very short ~20–30 minute half-life. Evidence is almost entirely animal/cell literature; not FDA-approved.
- Category
- GH Secretagogues
- Regulatory status
- Research Only — Preclinical Evidence
- Also known as
- des(1-3)IGF-1 / Truncated IGF-1
- Self-reports
- 2,337
Community
What 2,337 users report
2337 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 51% · Mixed 32% · Unfavorable overall 17%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Skin appearance
48
Appetite control
39
Energy
127
Mood
93
Focus
112
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
144
GI discomfort
118
Dizziness
92
Fatigue
89
Nausea
111
Self-reported dose per injection
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.05–2 mg
0.05–0.1 mg
7
0.1–0.2 mg
15
0.2–0.4 mg
18
0.4–0.6 mg
14
0.6–1 mg
8
1–2 mg
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Common discussion topics
timing21stacking19side effects17igf-1 des20
How repeat users are trending
Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 23 days · Based on 514 repeat reporters
Community charts use modeled aggregates when live Supabase snapshots are unavailable.
Research
Sources (6)
- Wiki study page →Source
- Wiki study page →Source
PubMed
Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice
Gillespie C, Read LC, Bagley CJ, et al. J Endocrinol. 1990
- Wiki study page →Source
PubMed
In vivo actions of IGF analogues with poor affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness
Walton PE, Dunshea FR, Ballard FJ. Prog Growth Factor Res. 1995
- Wiki study page →Source
PubMed
IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys
Tomas FM, Walton PE, Dunshea FR, et al. J Endocrinol. 1997
- Wiki study page →Source
PubMed
Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats
Read LC, Tomas FM, Howarth GS, et al. J Endocrinol. 1992
- Wiki study page →Source
ClinicalTrials.gov
des(1-3)IGF-1 / IGF-1 DES studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
Tools
Explore more
Explore
More ways to learn about IGF-1 DES from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about IGF-1 DES?
This page summarizes 2,337 anonymized self-reports from PeptIQ users who track IGF-1 DES, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for IGF-1 DES?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for IGF-1 DES?
6 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is IGF-1 DES safe to use?
This wiki does not assess safety or recommend use. IGF-1 DES is listed as Research Only — Preclinical Evidence. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of IGF-1 DES?
This wiki summarizes observational community reports and linked citations for IGF-1 DES. It does not assert therapeutic benefits. See the sources list on this page and the educational profile for IGF-1 DES for study-level context — not medical advice.
What is the legal status of IGF-1 DES?
IGF-1 DES is listed in PeptIQ as Research Only — Preclinical Evidence. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of IGF-1 DES?
Safety data quality for IGF-1 DES varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on IGF-1 DES?
This page links 6 sources for IGF-1 DES. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.